EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

Fadi Azar, Jules Deforges, Christelle Demeusoit, Patricia Kleinpeter, Christelle Remy, Nathalie Silvestre, Johann Foloppe, Laetitia Fend, Clémentine Spring-Giusti, Eric Quéméneur, Jean-Baptiste Marchand iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-009302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Fadi Azar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Transgene SA, Illkirch-Graffenstaden, France. Hauptthemen laut MEDLINE: Tumor Microenvironment, Interleukin-12, Vaccinia virus, CTLA-4 Antigen. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Transgene SA funded all the work presented in this publication..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

TG6050 was designed as an improved oncolytic vector, combining the intrinsic properties of vaccinia virus to selectively replicate in tumors with the tumor-restricted expression of recombinant immune effectors to modify the tumor immune phenotype. These properties might be of particular interest for “cold” tumors, either poorly infiltrated or infiltrated with anergic T cells.

Methods

TG6050, an oncolytic vaccinia virus encodes single-chain human interleukin-12 (hIL-12) and full-length anti-cytotoxic T-lymphocyte-associated antigen-4 (@CTLA-4) monoclonal antibody. The relevant properties of TG6050 (replication, cytopathy, transgenes expression and functionality) were extensively characterized in vitro . The biodistribution and pharmacokinetics of the viral vector, @CTLA-4 and IL-12, as well as antitumoral activities (alone or combined with immune checkpoint inhibitors) were investigated in several “hot” (highly infiltrated) and “cold” (poorly infiltrated) syngeneic murine tumor models. The mechanism of action was deciphered by monitoring both systemic and intratumoral immune responses, and by tumor transcriptome analysis. The safety of TG6050 after repeated intravenous administrations was evaluated in cynomolgus monkeys, with a focus on the level of circulating IL-12.

Results

Multiplication and propagation of TG6050 in tumor cells in vitro and in vivo were associated with local expression of functional IL-12 and @CTLA-4. This dual mechanism translated into a strong antitumoral activity in both “cold” and “hot” tumor models (B16F10, LLC1 or EMT6, CT26, respectively) that was further amplified when combined with anti-programmed cell death protein-1. Analysis of changes in the tumor microenvironment (TME) after treatment with TG6050 showed increases in interferon-gamma, of CD8+T cells, and of M1/M2 macrophages ratio, as well as a drastic decrease of regulatory T cells. These local modifications were observed alongside bolstering a systemic and specific antitumor adaptive immune response. In toxicology studies, TG6050 did not display any observable adverse effects in cynomolgus monkeys.

Conclusions

TG6050 effectively delivers functional IL-12 and @CTLA-4 into the tumor, resulting in strong antitumor activity. The shift towards an inflamed TME correlated with a boost in systemic antitumor T cells. The solid preclinical data and favorable benefit/risk ratio paved the way for the clinical evaluation of TG6050 in metastatic non-small cell lung cancer ( NCT05788926 trial in progress).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentInterleukin-12Vaccinia virusCTLA-4 AntigenOncolytic VirusesAnimalsMiceHumansFemaleMacaca fascicularisAntibodies, MonoclonalCell Line, TumorOncolytic VirotherapyNeoplasms

Stichwörter der Autor:innen

CytokineImmunotherapyMonoclonal antibodyOncolytic virusTumor microenvironment - TME

Substanzen

Interleukin-12CTLA-4 AntigenAntibodies, Monoclonal

Autor:innen und Institutionen

  • Transgene SA, Illkirch-Graffenstaden, France.
  • Transgene SA, Illkirch-Graffenstaden, France jem@transgene.fr.

ORCID-Profile: Jean-Baptiste Marchand

Förderung

  • Transgene SA funded all the work presented in this publication.

Zitieren

APA

Azar, F., Deforges, J., Demeusoit, C., Kleinpeter, P., Remy, C., Silvestre, N., Foloppe, J., Fend, L., Spring-Giusti, C., Quéméneur, E., & Marchand, J. B. (2024). TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009302

Vancouver

Azar F, Deforges J, Demeusoit C, Kleinpeter P, Remy C, Silvestre N, et al. TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009302

BibTeX
@article{Azar2024,
  author = {Azar, Fadi and Deforges, Jules and Demeusoit, Christelle and Kleinpeter, Patricia and Remy, Christelle and Silvestre, Nathalie and Foloppe, Johann and Fend, Laetitia and Spring-Giusti, Clémentine and Quéméneur, Eric and Marchand, Jean-Baptiste},
  title = {TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009302}
}
Kostenlos starten →